MET Activation in Lung Cancer and Response to Targeted Therapies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The hepatocyte growth factor receptor (MET) is a receptor tyrosine kinase (RTK) crucial for cellular processes like growth and survival.
• Aberrant MET activity, often due to mutations like MET amplification (METamp) or MET exon 14 skipping (METex14), drives tumorigenesis, particularly in lung cancer.
• MET is a key therapeutic target, leading to the development of MET tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

• To review the current therapeutic landscape for MET-positive cancers.
• To explore the diverse mechanisms underlying primary and acquired resistance to MET TKIs.
• To highlight the need for strategies to overcome therapeutic resistance in MET-driven cancers.

Main Methods:

• Literature review of studies on MET signaling in cancer.
• Analysis of clinical data regarding MET-targeted therapies.
• Examination of molecular mechanisms of resistance to MET inhibitors.

Main Results:

• MET alterations are common in various cancers, including lung cancer.
• MET TKIs have shown limited clinical efficacy due to significant resistance.
• Resistance mechanisms often involve off-target or bypass signaling pathways that evade MET inhibition.

Conclusions:

• Despite targeted therapies, resistance remains a major challenge in treating MET-positive cancers.
• Understanding resistance mechanisms is critical for developing more effective treatment strategies.
• Further research is needed to improve clinical outcomes for patients with MET-driven malignancies.